Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20746768 | 0.86 | ELANE (0.30) | ELANE | |
| SCHEMBL21299986 | 0.85 | ELANE (0.31) | ELANEHDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL21300012 | 0.85 | — | — | |
| SCHEMBL21698572 | 0.84 | ELANE (0.32) | ELANEMCHR1HDAC3HDAC1HDAC2 | |
| SCHEMBL20746748 | 0.77 | MIF (0.38) | — | |
| SCHEMBL14829667 | 0.75 | ALDH1A1 (0.40) | MCHR1HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL14838574 | 0.75 | ALDH1A1 (0.40) | MCHR1HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL20746766 | 0.74 | HDAC3 (0.38) | HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL21698575 | 0.73 | HDAC3 (0.37) | HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL20746751 | 0.73 | ALDH1A1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10822331-B2 | Processes for preparing ATR inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-11-03 | — | — | US | disclosed |
| US-10435397-B2 | — | — | 2019-10-08 | — | — | US | disclosed |
| US-20190202818-A1 | PROCESSES FOR PREPARING ATR INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2019-07-04 | — | — | US | disclosed |
| US-10208027-B2 | Processes for preparing ATR inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822331-B2 | Processes for preparing ATR inhibitors | ATR, ATRIP, CHEK1 | ELANE 4330/4885MCHR1 4560/4885HDAC3 2172/4885 |
| US-20190202818-A1 | PROCESSES FOR PREPARING ATR INHIBITORS | ATR, ATRIP, CHEK1 | ELANE 4347/4885MCHR1 4549/4885HDAC3 2188/4885 |
| US-10435397-B2 | — | ATR, ATRIP, TBK1 | ELANE 4169/4885MCHR1 4511/4885HDAC3 1641/4885 |
| US-10208027-B2 | Processes for preparing ATR inhibitors | ATR, ATRIP, CHEK1 | ELANE 4347/4885MCHR1 4549/4885HDAC3 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.